Indegene Limited, a healthcare solutions provider, has announced its financial results for the third quarter (Q3) of FY25, reporting strong revenue growth of 7% year-on-year (YoY) and an 11% increase in net profit. The company’s performance reflects continued expansion and operational efficiency in its core business segments.
For the quarter ending December 31, 2024, Indegene posted a consolidated net profit of ₹110 crore, compared to ₹99 crore in Q3 FY24.
Financial Highlights
- Revenue from operations – ₹720 crore, up 7% YoY from ₹673 crore in Q3 FY24 and up 4.9% QoQ from ₹687 crore in Q2 FY25.
- Total income – ₹758 crore, up from ₹687 crore in Q3 FY24.
- EBITDA – ₹151 crore, up from ₹131 crore in Q2 FY25.
- Net profit – ₹110 crore, up 11% YoY from ₹99 crore in Q3 FY24 and 20% QoQ from ₹92 crore in Q2 FY25.
- Earnings per share (EPS) – ₹4.59 (basic) and ₹4.55 (diluted), up from ₹4.42 in Q3 FY24 and ₹3.84 in Q2 FY25.
Segment Performance
Indegene’s business spans Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation.
- Enterprise Medical Solutions – ₹205 crore, up from ₹198 crore in Q2 FY25.
- Enterprise Commercial Solutions – ₹400 crore, up from ₹386 crore in Q2 FY25.
- Omnichannel Activation – ₹89 crore, up from ₹80 crore in Q2 FY25.
Key Updates
Indegene successfully completed its Initial Public Offering (IPO) in May 2024, raising ₹76 crore through a fresh issue of shares, along with an offer-for-sale component of ₹108 crore by existing shareholders.
The Board has approved the allotment of shares under the Employee Stock Option Plan (ESOP 2020) and Restricted Stock Unit (RSU 2020) plan, reinforcing employee participation in the company’s growth. Indegene has decided to sell its UK branch to its wholly owned subsidiary, Indegene Healthcare UK Limited, for ₹10 crore. The transaction is expected to be completed before March 31, 2025.
With a steady growth trajectory and increasing global footprint, Indegene remains an attractive investment in the healthcare solutions sector. Analysts note that the company’s rising revenue, stable margins, and global expansion strategy position it well for long-term growth.
Indegene plans to expand its healthcare technology services, invest in AI-driven solutions, and enhance its presence in international markets. The company is also focusing on strategic acquisitions to further strengthen its service offerings.
